Management of Hypertension with ACE Inhibitors
Contraindications and Precautions
- The American College of Cardiology and American Heart Association guidelines explicitly contraindicate dual ACE inhibitor therapy, as it provides no additional benefit while significantly increasing the risk of hypotension, hyperkalemia, and acute kidney injury 1
- High-quality RCT data demonstrate that simultaneous administration of RAS blockers increases cardiovascular and renal risk 1
Asthma Considerations
- The European Society of Cardiology guidelines state that ACE inhibitors are not contraindicated in asthma, but beta-blockers have a compelling contraindication in asthma 2
Treatment Options
- The European Society of Hypertension and European Society of Cardiology guidelines recommend adding a calcium channel blocker as the third agent for acute blood pressure management in patients already on perindopril and hydrochlorothiazide 3, 2, 1
- The optimal triple therapy combination is CCB + thiazide + ACEI, as recommended by the ESH/ESC, NICE, Taiwan, and China guidelines 3
- Amlodipine 5-10 mg daily is an appropriate choice for a dihydropyridine CCB, with complementary mechanisms and no contraindications in this patient 2, 1
Monitoring and Safety
- Monitor for hypotension when adding any third agent, especially given the patient is already on two antihypertensive medications 2
- Check serum creatinine and potassium within 2-4 weeks of any medication adjustment involving ACE inhibitors 1
- Ensure the patient's blood pressure is not a hypertensive emergency, but rather Stage 2 hypertension that can be managed with adjustments to the regimen 1